Table 1. Baseline characteristics of participants in the time to CD4:CD8 normalization and time to ADI/death analyses.
| Variable | CD4:CD8 Normalization (n = 4206), n (%) | ADI/Death (n = 3405), n (%) |
| Age at cART initiationa | 40 (34–47) | 40 (34–46) |
| Gender | ||
| Female | 779 (19%) | 644 (19%) |
| Male/Transgender | 3426 (81%) | 2761 (81%) |
| Province | ||
| British Columbia | 2056 (49%) | 1731 (51%) |
| Ontario | 925 (22%) | 767 (23%) |
| Quebec | 1225 (29%) | 907 (27%) |
| HIV risk factor | ||
| Men who have sex with men | 1727 (41%) | 1420 (42%) |
| Injection drug use | 996 (24%) | 832 (24%) |
| Heterosexual | 1268 (30%) | 1066 (31%) |
| Endemic country | 378 (9%) | 322 (9%) |
| Blood transfusion | 102 (3%) | 86 (3%) |
| Mother-to-child transmission | 25 (1%) | 21 (1%) |
| Unknown | 1265 (30%) | 997 (29%) |
| Hepatitis C co-infection | ||
| Yes | 940 (22%) | 781 (23%) |
| No | 2135 (51%) | 1662 (49%) |
| Unknown | 1131 (27%) | 962 (28%) |
| Baseline CD4+ T-cell counta | 190 (100–276) | 200 (120–280) |
| Baseline HIV RNA (log10 copies/mL)a | 4.9 (4.4–5.0) | 4.9 (4.4–5.0) |
| Suppressed HIV RNA at baseline | 113 (3%) | 71 (2%) |
| Year of cART initiationa | 2005 (2002–2007) | 2005 (2002–2007) |
| Baseline cART | ||
| NNRTI-based | 1902 (44%) | 1620 (46%) |
| Boosted PI-based | 1946 (45%) | 1530 (44%) |
| Single PI-based | 358 (8%) | 255 (7%) |
| CD4:CD8 measurements per year | ||
| <3 | 740 (18%) | 589 (17%) |
| 3–4 | 946 (22%) | 759 (22%) |
| 5–6 | 1504 (36%) | 1218 (36%) |
| >6 | 1016 (24%) | 839 (25%) |
a
Median (interquartile range).
cART, Combination antiretroviral therapy; NNRTI, Non-nucleoside reverse transcriptase inhibitor; PI, Protease inhibitor.